alexa Conestat alfa for the treatment of angioedema attacks.
Haematology

Haematology

Journal of Hematology & Thromboembolic Diseases

Author(s): Davis B, Bernstein JA

Abstract Share this page

Abstract Recently, multiple C1 inhibitor (C1-INH) replacement products have been approved for the treatment of hereditary angioedema (HAE). This review summarizes HAE and its current treatment modalities and focuses on findings from bench to bedside trials of a new C1-INH replacement, conestat alfa. Conestat alfa is unique among the other C1-INH replacement products because it is produced from transgenic rabbits rather than derived from human plasma donors, which can potentially allow an unlimited source of drug without any concern of infectious transmission. The clinical trial data generated to date indicate that conestat alfa is safe and effective for the treatment of acute HAE attacks.
This article was published in Ther Clin Risk Manag and referenced in Journal of Hematology & Thromboembolic Diseases

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • International Conference on Hematology and Oncology 
    July 01-2017,Bangkok,Thailand

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords